Introduction: April 21, 2019, the highly anticipated China CNS College was officially established, and successfully launched in Shunde in Guangdong. Well -known experts at home and abroad witnessed this exciting moment. In order to further enhance the standardized diagnosis and treatment of malignant tumors in the country,
strengthens the understanding and prevention of brain metastases, especially lung cancer, especially lung cancer brain metastasis. On April 21, 2019, China CNS College was officially established and successfully launched in Shunde, Guangdong. Discipline and scholars from well -known experts and scholars from various disciplines such as oncology, respiratory department, thoracic surgery, radiotherapy, neurosurgery, etc., focusing on the current status and new progress of brain metastasetoma treatment, and dedicated a wonderful game to fellows in the country in the country. Academic feast.
Launching Ceremony
This meeting was Professor of Professor Rolf A. Stahel, Professor ROLF A. Stahel at the Cancer Hospital of Sun Yat -sen University, Professor of Radiology , King of the Academy of Medical Sciences, Professor Mu Yongguan Wait as the chairman of the conference. Professor Zhang Li said that patients with brain metastasel, clinically, have a high incidence and poor prognosis, which seriously affects patients' survival benefits and quality of life. The establishment of the CNS College aims to gather the power of more discipline clinical experts through this platform, and contribute to the comprehensive prevention and treatment of brain metastases, especially lung cancer, and brain metastasis. At the same time, the quality of life of patients will be improved at the same time, and it will eventually benefit more clinical patients.
opened the opening ceremony of
. After the exciting launching ceremony, the conference entered the academic preaching session. Experts pointed out that the occurrence of brain metastases seriously threatened patients' lives. At present, the treatment methods commonly used for brain metastases include surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy . Zhejiang Cancer Hospital chest on the chest, Professor Fan Yun, mentioned that Flaura studies show that for the patients with EGFR sensitive mutant positive NSCLC brain metastasis patients, Osteni's standard treatment is significantly extended to the median PFS (15.2 months vs. 9.66.66.66.6 A month), reduce the risk of progress of intracranial disease by 53%, and there are fewer progress in CNS in patients with Oshininib groups. It is also less progressive due to the new cns lesions, which can prevent brain rotation. Professor Rolf A. Stahel emphasizes that compared with other EGFR-TKI patients with EGFR sensitive mutant positive NSCLC patients, the third-generation EGFR-TKI Oshitinib provides longer PFS, fewer side effects, better CNS efficacy At present, the highest -level recommendation of NCCN Guide and European ESMO Guide is a preferred plan for the current first -line treatment. At the same time, it is also looking forward to the approval of Oshitinib in China's first -line indications.
Professor Fan Yun and Professor Liu Anwen,
, started with hot discussions on hot issues such as brain transfer prevention strategies, the timing of Olinib application, and joint therapy model discussion of brain transfer prevention strategies, Olinibic applications, and joint treatment. Participants have expressed their benefits. At the end of
at the
conference, Professor Zhang Li pointed out in the summary that brain metastasel is an important issue that needs to be solved in clinical practice. Patients are the core, led by clinical experts, social organizations and related units to participate in, and will launch a series of project activities in 2019. Full online and offline coverage, multi -department co -linkage, strengthen academic publicity and exchanges. We look forward to more clinicians Use scientific power to protect the lives of more patients!
